Brief: Paradigm Biopharmaceuticals Secures USD$27 Million Convertible Note Facility
01/07/2025 24:44
July 1 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX: PARADIGM SECURES USD $27 MILLION CONVERTIBLE NOTE FACILITY TO ADVANCE PHASE 3 KNEE OA STUDY Further company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paradigm Biopharmaceuticals
See all newsBrief: Paradigm Biopharmaceuticals Says Board Initiates Voluntary Administration
Brief: Paradigm Biopharmaceuticals Seeks Trading Halt
Australia's Paradigm Biopharmaceuticals slips on discounted placement
Brief: Paradigm Biopharmaceuticals Says Co Completes A$14 Mln Placement
Brief: Paradigm Biopharmaceuticals Requests Trading Halt